Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation.
To discuss the value of intratympanic dexamethasone (IT-DEX) perfusion for sudden sensorineural hearing loss (SSNHL), clinically and in an animal model. Retrospective case review of 10 patients with SSNHL treated with IT-DEX. The findings are correlated with this institution's previous findings from a study of IT-DEX in guinea pigs. Ambulatory tertiary otologic referral center. Sequential patients with SSNHL who chose IT-DEX treatment. Dexamethasone 0.5 mg was injected transtympanically and bathed the round window for 20 minutes. Animal study: 79 ears were randomized into five groups: control, IT-DEX versus intravenous (IV)-DEX, IT-DEX with histamine, IT-DEX with hyaluronic acid, and IT-DEX with dimethylsulfoxide. Clinical study: postprocedure audiometry. Animal study: perilymph steroid concentration. IT-DEX results in significant hearing improvement and in significantly higher perilymph concentration of steroid than IV-DEX. IT-DEX is an appropriate treatment option for the treatment of SSNHL. Further study of dosages and frequency of administration is warranted.